Ciprobel (ciprofloxacin) coated tablets 500 mg. №14

Description

Ciprobel is indicated for the treatment of the following infections (see the Sections “application Features” and “Pharmacological properties”). Before starting therapy it is necessary to pay special attention to all available information on resistance to ciprofloxacin.
Official recommendations for the proper use of antibacterial drugs should be taken into account.
adults
Lower respiratory tract infections caused by gram-negative bacteria:
exacerbation of chronic obstructive pulmonary disease;
bronchopulmonary infection in patients with cystic fibrosis or bronchiectasis;
pneumonia.
Chronic purulent otitis media.
Exacerbation of chronic sinusitis, especially if it is caused by gram-negative bacteria.
Urinary tract infections.
Infectious lesions of the sexual system:
gonococcal urethritis and cervicitis caused by sensitive strains of Neisseria gonorrhoeae;
orchiepididymitis, in particular caused by sensitive strains of Neisseria gonorrhoeae;
pelvic inflammatory diseases, particularly those caused by sensitive strains of Neisseria gonorrhoeae.
Gastrointestinal infections (such as traveler’s diarrhea).
Intra-abdominal infection.
Skin and soft tissue infections caused by gram-negative bacteria.
Severe otitis media of the outer ear.
Infections of bones and joints.
Prevention of invasive infections caused by Neisseria meningitidis .
Pulmonary form of anthrax (prevention after contact and radical treatment).
Ciprofloxacin can be used for the management of patients with neutropenia and hyperthermia in case of suspicion about the bacterial infectious Genesis of fever in this category of patients.

Children and teenagers

Bronchopulmonary infections in cystic fibrosis caused by Pseudomonas aeruginosa )
Complicated urinary tract infections and pyelonephritis.
Pulmonary form of anthrax (prevention after contact and radical treatment).
Ciprofloxacin can be used to treat severe infections in children and adolescents when the doctor considers it necessary.

Treatment should be started by a doctor who has experience in treating cystic fibrosis and / or severe infections in children and adolescents (see the Sections “application Features” and “Pharmacological properties”).